UNSPSC 51111645: Pralatrexate

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C23H23N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8Q8I19Q20, more generally known as pralatrexate. European Medicines Agency schedules pralatrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32989. The term PRALATREXATE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.

Most nations schedule pralatrexate under HS 29335995 and SITC 51576. As of Q4 2014, PRALATREXATE remains the US FDA Preferred Term for this commodity. Pralatrexate bears US NLM identifiers UMLS ID C0879404 and NCI Concept Code C2250. SMILES: C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.

UNSPSC 51111645 Pralatrexate is a Commodity code that designates a specific antifolate chemotherapy drug used in treating peripheral T-cell lymphoma and other hematologic malignancies. State and local governments procure this pharmaceutical through their health benefit and pharmacy benefit programs, primarily when covering treatment for eligible beneficiaries under Medicaid, employee health plans, or corrections-system inmate medical care. The issuing bodies soliciting under this code are state health and human services departments and state corrections agencies managing centralized pharmacy procurement and therapeutic drug formularies. The scope encompasses both the acquisition of the drug itself and the contracting mechanisms through which states negotiate pricing, volume commitments, and direct relationships with manufacturers or their authorized distributors to manage costs and ensure consistent supply for covered populations.

The Texas Health and Human Services Commission (HHS) issued Request for Information RFI No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities and market intelligence for implementing a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI solicits information from vendors about their capacity to establish direct contracts with self-insured employee group health plans and state agencies outside of traditional pharmacy benefit manager (PBM), group purchasing organization (GPO), and wholesaler arrangements, with particular interest in vendors' experience with direct contracting, flexibility to negotiate net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. This exploratory phase precedes a formal RFP and reflects the state's intent to develop detailed procurement specifications and implementation timelines for subsequent competitive solicitations. The source does not identify other recent state or local opportunities tagged to this code.